TLDR
- CODX spiked 33% then erased all gains after a $13B South Asia expansion deal
- Co-Diagnostics eyes $13B market but CODX stock couldn’t hold its morning surge
- CODX hit $4.00, then crashed back South Asia deal failed to impress traders
- Big territory deal, bigger selloff CODX stock tells a familiar small-cap story
- CoSara expands into five nations but CODX stock gives back every early-morning gain
CODX stock jumped sharply before pulling back to $2.585, down 2.46%. The move followed a major territorial expansion announcement for its Indian joint venture, CoSara Diagnostics. CODX stock opened near $3.00, spiked to nearly $4.00, then sold off steadily through midday.
CODX Stock Rallies Hard on South Asia News Before Fading
Co-Diagnostics signed an agreement to expand CoSara’s commercial territory across South Asia. The deal adds Bangladesh, Pakistan, Nepal, and Sri Lanka to the joint venture’s distribution reach. Furthermore, the expansion raises the addressable market to an estimated $13.0 billion.
CoSara is a joint venture between Co-Dx and Ambalal Sarabhai Enterprises Limited, the ASE Group. The venture focuses on molecular diagnostic products across the South Asian region. Additionally, CODX stock had already been trading quietly before this announcement triggered the morning surge.
The expansion supports commercialization of the CoSara PCR Pro point-of-care instrument and the SARAGENE product line. However, both products still require regulatory approvals in each new jurisdiction. The company is actively evaluating regulatory pathways and identifying distribution partners in each market.
CoSara Targets $13 Billion Market Across Five Nations
CoSara CEO Mohal Sarabhai stated that South Asia presents a large and fast-growing market for molecular diagnostics. He added that the region has significant demand for reliable, accessible, and non-invasive testing solutions. CoSara plans to address tuberculosis, HPV and upper respiratory infections across these markets.
Co-Diagnostics CEO Dwight Egan said the expansion reflects the company’s broader strategy of building regional infrastructure ahead of commercialization. He emphasized that local manufacturing and distribution capabilities are central to this plan. CODX stock carries a long-term growth thesis tied to global PCR deployment.
Co-Diagnostics operates in the United States, South Asia, and the Middle East and North Africa. The company uses a patented platform for developing molecular diagnostic tests. Therefore, CODX stock remains linked to the company’s ability to execute across multiple international markets.
CODX Stock Pulls Back Despite Expansion Progress
CoSara plans to host a virtual distributor information session in Q2 2026. An in-person distributor meeting and training event will follow later that summer. The commercial rollout timeline for CODX stock catalysts extends into the second half of 2026.
The morning chart showed CODX stock climbing nearly 33% before reversing those gains entirely. Selling pressure dominated from 10:00 AM onward, pushing the price below the previous close. CODX stock stabilized near $2.585, suggesting the market absorbed the news without a full collapse.
Co-Diagnostics remains a small-cap molecular diagnostics company with an active international growth strategy. The company’s joint ventures and distribution agreements continue to expand its global footprint. As a result, CODX stock will likely remain sensitive to commercial milestone announcements going forward.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
